243 results on '"Dworzak, Michael N."'
Search Results
2. Optimized cytogenetic risk-group stratification of KMT2A-rearranged pediatric acute myeloid leukemia
3. CD371-positive pediatric B-cell acute lymphoblastic leukemia: propensity to lineage switch and slow early response to treatment
4. Risk factors in DUX4-positive childhood and adolescent B-cell acute lymphoblastic leukemia
5. Selective pressures of platinum compounds shape the evolution of therapy-related myeloid neoplasms
6. Towards Self-explainable Transformers for Cell Classification in Flow Cytometry Data
7. FCM marker importance for MRD assessment in T‐Cell Acute Lymphoblastic Leukemia: An AIEOP‐BFM‐ALL‐FLOW Study Group Report
8. FCM marker importance for MRD assessment in T‐cell acute lymphoblastic leukemia: An AIEOP‐BFM‐ALL‐FLOW study group report.
9. Measurable Residual Disease and Fusion Partner Independently Predict Survival and Relapse Risk in Childhood KMT2A-Rearranged Acute Myeloid Leukemia: A Study by the International Berlin-Frankfurt-Münster Study Group
10. Azacitidine (Vidaza®) in Pediatric Patients with Relapsed Advanced MDS and JMML: Results of a Phase I/II Study by the ITCC Consortium and the EWOG-MDS Group (Study ITCC-015).
11. Adolescents and young adults with acute lymphoblastic leukemia and acute myeloid leukemia: Characteristics and treatment outcome
12. Case Report: Refractory Cytopenia With a Switch From a Transient Monosomy 7 to a Disease-Ameliorating del(20q) in a NHEJ1-Deficient Long-term Survivor
13. Automated identification of cell populations in flow cytometry data with transformers
14. Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: results from Study AML-BFM 2004
15. Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel
16. UMAP Based Anomaly Detection for Minimal Residual Disease Quantification within Acute Myeloid Leukemia
17. In need of special care: adolescent and young adult patients with cancer
18. Prognostic significance of additional cytogenetic aberrations in 733 de novo pediatric 11q23/MLL-rearranged AML patients: results of an international study
19. The variable biological signature of refractory cytopenia of childhood (RCC), a retrospective EWOG-MDS study
20. CD11b is a therapy resistance– and minimal residual disease–specific marker in precursor B-cell acute lymphoblastic leukemia
21. Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study
22. Thiamine-responsive megaloblastic anemia (TRMA) in an Austrian boy with compound heterozygous SLC19A2 mutations
23. Cure and care for children and adolescents with acute myeloid leukemia in Middle and Eastern European countries: part II
24. CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment: setting the stage for anti-CD20 directed immunotherapy
25. The inferior prognosis of adolescents with acute lymphoblastic leukaemia (ALL) is caused by a higher rate of treatment-related mortality and not an increased relapse rate – a population-based analysis of 25 years of the Austrian ALL-BFM (Berlin-Frankfurt-Münster) Study Group
26. CNS irradiation in pediatric acute myleoid leukemia: Equal results by 12 or 18 Gy in studies AML-BFM98 and 2004
27. Phospho-Profiling Linking Biology and Clinics in Pediatric Acute Myeloid Leukemia
28. Flow-Cytometric Monitoring of Minimal Residual Disease in Pediatric Patients With Acute Myeloid Leukemia: Recent Advances and Future Strategies
29. Prognostic relevance of dic(9;20)(p11;q13) in childhood B-cell precursor acute lymphoblastic leukaemia treated with Berlin-Frankfurt-Münster (BFM) protocols containing an intensive induction and post-induction consolidation therapy
30. AIEOP-BFM consensus guidelines 2016 for flow cytometric immunophenotyping of Pediatric acute lymphoblastic leukemia
31. Long-term outcome of initially homogenously treated and relapsed childhood acute lymphoblastic leukaemia in Austria – A population-based report of the Austrian Berlin-Frankfurt-Münster (BFM) Study Group
32. Bone Marrow Assessment in Langerhans Cell Histiocytosis
33. Treatment with caspofungin in immunocompromised paediatric patients: a multicentre survey
34. Philadelphia chromosome-positive mature B-cell (Burkitt cell) leukaemia
35. Reduced Interferon-γ Expression in Peripheral Blood Mononuclear Cells of Infants with Severe Respiratory Syncytial Virus Disease
36. CD99 (MIC2) expression in paediatric B-lineage leukaemia/lymphoma reflects maturation-associated patterns of normal B-lymphopoiesis
37. Skin-associated lymphocytes in the peripheral blood of patients with atopic dermatitis: Signs of subset expansion and stimulation
38. CD371 cell surface expression: a unique feature of DUX4-rearranged acute lymphoblastic leukemia
39. Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia
40. Automated Flow Cytometric MRD Assessment in Childhood Acute B‐ Lymphoblastic Leukemia Using Supervised Machine Learning.
41. Clofarabine, high-dose cytarabine and liposomal daunorubicin in pediatric relapsed/refractory acute myeloid leukemia: a phase IB study
42. MEMO and paediatric oncology – Yes, we can!
43. Adolescents and young adults with acute lymphoblastic leukemia and acute myeloid leukemia
44. Characteristics and outcome in patients with central nervous system involvement treated in European pediatric acute myeloid leukemia study groups
45. MEF2C-dysregulated pediatric T-cell acute lymphoblastic leukemia is associated withCDKN1Bdeletions and a poor response to glucocorticoid therapy
46. Chronic stress induces CD99, suppresses autophagy, and affects spontaneous adipogenesis in human bone marrow stromal cells
47. First experience of the AML-Berlin-Frankfurt-Münster group in pediatric patients with standard-risk acute promyelocytic leukemia treated with arsenic trioxide and all-trans retinoid acid
48. Flow diagnostics essential code: a simple and brief format for the summary of leukemia phenotyping
49. AIEOP‐BFM consensus guidelines 2016 for flow cytometric immunophenotyping of Pediatric acute lymphoblastic leukemia.
50. MEF2C-dysregulated pediatric T-cell acute lymphoblastic leukemia is associated with CDKN1B deletions and a poor response to glucocorticoid therapy.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.